Stay updated on the most recent developments in Symeres.
Nijmegen (the Netherlands) – 19th November 2020 MercachemSyncom today announced that it will change its name […]
MercachemSyncom has a well-established track record in advancing drug-discovery programs for both large pharma and small […]
Nijmegen (the Netherlands) – 9th November 2020 MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, […]
In recent years, MercachemSyncom has achieved continuous and steady growth of its business. The acquisition of […]
Bresso (Italy), Villigen (Switzerland) and Nijmegen (the Netherlands) 28 October 2020 Axxam, leadXpro and MercachemSyncom today […]
Delivery of an innovative 80,000 compound lead-like library for HTS and a cutting-edge parallel medicinal chemistry […]
Groningen OPEN starts this week. Four companies from Northern Netherlands are looking for start-ups with innovative […]
Would you be surprised to learn of MercachemSyncom’s involvement in optimizing LED emitters? With our reputation […]
MercachemSyncom, the leading mid-sized European drug-discovery contract research organization (CRO) offering drug-discovery research and development services, […]
Drug-discovery outsourcing in the pharmaceutical industry has changed dramatically in the past 20 years. While the […]
Check out the pupblications and patents that came out this summer!
MercachemSyncom has been selected by Hercules Pharmaceutical B.V., as the chemical partner for their project on second-generation AhR inhibitors.
The so-called three component Povarov reaction was used to prepare a tetrahydroquinoline from an aniline, an aldehyde and an enamine. This reaction had been reported before in literature but this was the first time it was applied to synthesize an API.
MercachemSyncom is pleased to announce several changes in its organization to position the company for the next phase of growth and development.
We are excited to tell you that this month we celebrated the opening of our first office in the USA at the Cambridge Innovation Center (CIC) at One Broadway, Cambridge, MA. The office will be managed by Dr. Bart DeCorte, Vice President of Business Development for North America.
Bionetix announced they have signed a joint multiyear integrated drug-discovery project, starting from target identification (TI) up to clinical candidate selection on an undisclosed target aimed at acute myeloid leukemia (AML).
It is our great pleasure to announce today that MercachemSyncom has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands.